IF1 Attenuates Sensitivity of HCC Cells to Sorafenib After Insufficient RFA in vitro, and Indicates Poor Disease Free Survival in HCC Patients After Sorafenib Therapy. The gene discussed is ATP5IF1; the disease is hepatocellular carcinoma.